Celyad Oncology (Euronext: CYAD) (the "Company" or "Celyad") is pleased to announce Matt Kane as its new Chief Executive ...

This report is a review of recent and emerging trends that promise to make radiation oncology for prostate cancer more ...

SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today ...

American Oncology Institute (AOI) at Citizens Specialty Hospital in Hyderabad has successfully treated a 93-year-old male ...

The Academy of Oncology Nurse & Patient Navigators (AONN+) is pleased to announce that Candice Roth, MSN, RN, CENP, has ...

Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad”) is pleased to announce Matt Kane as its new Chief Executive Officer (CEO), effective as of October 1st, 2024. Matt Kane is a ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 15.28% ...

MONT-SAINT-GUIBERT, Belgium, September 16, 2024--(BUSINESS WIRE)--Regulatory News: Celyad Oncology (Euronext: CYAD) (the "Company" or "Celyad") is pleased to announce Matt Kane as its new Chief ...

Memorial Sloan Kettering Cancer Center in New York City has appointed two oncology chiefs.

Pure Protein L.L.C. proudly announces the appointment of Dr. Rico Buchli as Chief Scientist. In his new role, Dr. Buchli will ...

Kura Oncology Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of 0.00% with a gross margin of -4.18%. The profit margin, also known as the ...